BioCardia, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BioCardia, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $6.27M, a 36805.88% increase year-over-year.
- BioCardia, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $832.00K.
- BioCardia, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $17.00K, a 87.86% decline year-over-year.
- BioCardia, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $2.47M, a 92.00% increase year-over-year.
- BioCardia, Inc. stock issued during period, value, new issues for fiscal 2022 was $3.40M, a 75.23% increase from fiscal 2021.
- BioCardia, Inc. stock issued during period, value, new issues for fiscal 2021 was $1.94M.
- BioCardia, Inc. stock issued during period, value, new issues for fiscal 2019 was $9.20M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-09-30 | $6.27M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $832.00K 10-Q · filed 2024-11-13 | |
| 2023-09-30 | $17.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $2.47M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $3.40M 10-K · filed 2024-03-27 | |
| 2022-09-30 | $140.00K 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $1.29M 10-Q · filed 2022-11-09 | |
| 2021-12-31 | $1.94M 10-K · filed 2023-03-29 | |
| 2021-03-31 | $1.93M 10-Q · filed 2022-11-09 | |
| 2020-06-30 | $10.34M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $9.20M 10-K · filed 2021-03-30 | |
| 2019-09-30 | $9.26M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |